Nitta T, Sato K, Yagita H, Okumura K, Ishii S
Department of Immunology, Juntendo University School of Medicine, Tokyo, Japan.
Lancet. 1990 Feb 17;335(8686):368-71. doi: 10.1016/0140-6736(90)90205-j.
The results of specific targeting therapy by use of lymphokine-activated killer (LAK) cells treated with bispecific antibody in 10 patients with malignant glioma were compared with the results of therapy with untreated LAK cells in 10 other patients. Both treated and untreated cells were given locally. The bispecific antibody was an anti-CD3 monoclonal antibody (mAb) chemically conjugated to anti-glioma mAb. Of the 10 patients given specific targeting therapy, 4 showed regression of tumour, and in another 4 patients computed tomography and histology suggested eradication of the glioma cells left behind after surgery. No recurrence was detected in the 10 to 18 months of follow-up. Patients receiving untreated LAK cells had recurrences within 1 year except in 1 case, and 8 patients died within 4 years. So far specific targeting therapy seems to be a new useful form of adoptive immunotherapy.
将10例恶性胶质瘤患者使用双特异性抗体处理的淋巴因子激活杀伤细胞（LAK细胞）进行特异性靶向治疗的结果，与另外10例患者使用未处理的LAK细胞治疗的结果进行了比较。处理过的和未处理的细胞均进行局部给药。双特异性抗体是一种化学偶联抗胶质瘤单克隆抗体（mAb）的抗CD3单克隆抗体。在接受特异性靶向治疗的10例患者中，4例肿瘤出现消退，另外4例患者的计算机断层扫描和组织学检查提示手术遗留的胶质瘤细胞被清除。在10至18个月的随访中未检测到复发。接受未处理LAK细胞的患者除1例外在1年内出现复发，8例患者在4年内死亡。到目前为止，特异性靶向治疗似乎是一种新的有用的过继性免疫治疗形式。
